News | June 12, 2022
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amarex Clinical Research guides its client to phase II of FDA trials
Tislelizumab is now approved in nine indications in China
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
New Director supports NASDAQ rule on diversity
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Subscribe To Our Newsletter & Stay Updated
